Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Imbruvica
Pharma
Trial results show value of Lilly's Jaypirca in front-line CLL
By nailing the primary endpoint in a trial of Jaypirca, Eli Lilly has brought the drug closer to becoming available to a broader group of patients.
Kevin Dunleavy
Sep 8, 2025 11:37am
BeOne widens BTK lead over AstraZeneca
Aug 6, 2025 10:55am
Lilly's BTK Jaypirca makes the grade versus Imbruvica
Jul 29, 2025 4:56pm
On 2nd glance, analyst reverses rosy view on IRA cuts
Aug 19, 2024 5:21pm
AZ makes case for Calquence in another blood cancer type
Jun 17, 2024 11:25am
AZ clinches early Calquence win in untreated MCL
May 2, 2024 10:24am
